Protective Effect of Antagonist of High‐mobility Group Box 1 on Lipopolysaccharide‐Induced Acute Lung Injury in Mice
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We explored the effects of recombinant A‐box (rA‐box), a specific blockade for endogenous high mobility group box 1 (HMGB1) protein, on acute lung inflammation induced by lipopolysaccharide (LPS) in vivo. Acute lung injury (ALI) was produced successfully by intratracheal administration of LPS (10 μ g/mouse) in male BALB/c mice. rA‐box (0.3, 0.6 mg/mouse, i.p.) was administered 30 min prior to or 2 h after LPS exposure. Bronchoalveolar lavage fluid (BALF) was obtained to measure chemokines, proinflammatory cytokines, total cell counts and proteins at the indicated time points. It was found that rA‐box caused a significant reduction in the total cells and neutrophils in BALF, a significant reduction in the W/D ratio and protein leakage at 24 h after LPS challenge. In addition, rA‐box was also believed to have downregulated the expression of LPS‐induced chemokines (keratinocyte‐derived chemokine) and proinflammatory cytokines, including early mediator TNF‐a and late mediator HMGB1. These findings confirm the significant protection of rA‐box against LPS‐induced ALI, and the effect mechanism of rA‐box was associated with decreasing the expression of chemokines and proinflammatory cytokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372
The cytokine activity of HMGB1
Yang, H., Wang, H., Czura, C. J., & Tracey, K. J. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1104648 · Cited by 545
The extracellular release of HMGB1 during apoptotic cell death
Bell, C. W., Jiang, W., Reich, C. F., & Pisetsky, D. S. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00616.2005 · Cited by 538
Youn, J. H., Oh, Y. J., Kim, E. S., Choi, J. E., & Shin, J.-S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.5067 · Cited by 281
Cited by
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
“The antagonist HMGB1 A box peptide (62)”
Targeting Inflammation Driven by HMGB1
Yang, H., Wang, H., & Andersson, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00484 · Cited by 636
Targeting HMGB1 in inflammation
Yang, H., & Tracey, K. J. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.019 · Cited by 351
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, D., Roviello, G. N., & Montesarchio, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.001 · Cited by 334
Sterile inflammation and pregnancy complications: a review
Nadeau-Vallée, M., Obari, D., Palacios, J., Brien, M.-È., Duval, C., Chemtob, S., & Girard, S. (2016) · Reproduction · doi:10.1530/rep-16-0453 · Cited by 275
Metadata
- Authors
- Gong, Q., Xu, J. ‐., Yin, H., Liu, S. ‐., Duan, L. ‐., & Bian, Z. ‐.
- Venue
- Scandinavian Journal of Immunology
- Publisher
- Wiley
- Published
- 2008-12-18
- Volume
- 69
- Issue
- 1
- Pages
- 29-35
- ISSN
- 0300-9475 (ISSN-L)
- 1365-3083
- OpenAlex
- W2083866748
- Cited by
- 66
- References
- 4
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protective Effect of Antagonist of High‐mobility Group Box 1 on Lipopolysaccharide‐Induced Acute Lung Injury in Mice. https://app.cochat.ai/papers/10.1111/j.1365-3083.2008.02194.x
- The paper
- Gong, Q., Xu, J. ‐., Yin, H., Liu, S. ‐., Duan, L. ‐., & Bian, Z. ‐. (2009). Protective Effect of Antagonist of High‐mobility Group Box 1 on Lipopolysaccharide‐Induced Acute Lung Injury in Mice. Scandinavian Journal of Immunology. https://doi.org/10.1111/j.1365-3083.2008.02194.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.